Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs with Concurrent Chemoradiotherapy in Cervical Carcinoma
NCT04443296Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in cervical carcinoma, sponsored by Sun Yat-sen University. Primary endpoints: Toxicity Evaluation and Feasibility of CCRT in combination with TIL successful infusion. Status: unknown.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
cervical carcinoma
Beyond the preview
Go deeper on NCT04443296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443296.